Drugs Made In America Acquisition approved Omnibus Amendment No. 3 to its merger agreement with Power Analytics Global to refine deal economics and safeguards. The amendment provides for sponsor founder share forfeiture and earnouts, authorizes a public rights tender or exchange at $0.25–$0.35 per right, and resets minimum cash to a $30 million target with a $15 million floor tied to valuation and ownership adjustments. It permits additional pre-close financing, pre-approves a contingent three-party combination if satisfied by Sep 30, 2026, and requires an independent fairness opinion due to related-party considerations.
Agreement details:
- Agreement type: Omnibus Amendment No. 3 to Merger Agreement
- Counterparty: Power Analytics Global
- Signed / Effective: Jul 14 2026 / same
- Duration / Termination: Until closing
- Reason: Refine economics, address rights, and add related-party safeguards
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.